Suita, Japan

Eri Ichibayashi

This inventor holds 1 USPTO granted patent. Top assignee: Sumitomo Pharma Co., Ltd.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eri Ichibayashi: Innovator in Transdermal Absorption Technology

Introduction

Eri Ichibayashi is a notable inventor based in Suita, Japan. She has made significant contributions to the field of pharmaceutical technology, particularly in the development of transdermal absorption preparations. Her innovative work aims to enhance the efficacy and stability of medications.

Latest Patents

Eri Ichibayashi holds a patent for a transdermal absorption preparation. This invention relates to a formulation that can maintain a blood concentration sufficient to exert the efficacy of tandospirone. It also demonstrates good storage stability against heat, humidity, and light. The preparation includes tandospirone or a pharmaceutically acceptable salt thereof, along with levulinic acid, which improves the skin permeability of the active ingredient.

Career Highlights

Eri Ichibayashi is associated with Sumitomo Pharma Co., Ltd., where she continues to work on innovative pharmaceutical solutions. Her dedication to research and development has positioned her as a key figure in her field. With a focus on improving drug delivery systems, she has contributed to advancements that benefit patients and healthcare providers alike.

Collaborations

Eri collaborates with talented colleagues, including Masayasu Tanaka and Yuki Ikeda. These partnerships enhance her research efforts and foster a collaborative environment for innovation.

Conclusion

Eri Ichibayashi's work in transdermal absorption technology exemplifies her commitment to advancing pharmaceutical science. Her innovative patent and collaborations highlight her role as a leading inventor in her field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…